Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib redifferentiation in radioiodine-refractory thyroid cancer
NL-OMON55301Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenvatinib in well-differentiated thyroid cancer (WDTC) and thyroid cancer (2 arms), sponsored by Amsterdam University Medical Center. Started Jan 2022; status: completed.
02
Drugs
lenvatinib
03
Conditions
well-differentiated thyroid cancer (WDTC)thyroid cancer
Beyond the preview
Go deeper on NL-OMON55301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55301.